Abeona Therapeutics Inc.
Abeona Therapeutics Inc. (ABEO) is a clinical-stage biotechnology company focused on developing gene and cell therapies for rare genetic diseases. With a market capitalisation of about $280.49 million, Abeona operates in a high-risk, high-reward segment where clinical progress, regulatory decisions and partnership deals can materially affect value. Investors should know that outcomes in this sector are often binary — positive trial data or approvals can drive significant upside, while setbacks, delays or financing needs can weigh heavily on the share price. Development timelines are typically long and capital intensive. This summary is educational only and not personalised investment advice; consider your risk tolerance, investment horizon and the possibility of losing capital before taking action. Conduct further due diligence on Abeona’s pipeline, trial results, financial position and regulatory environment, and consult a regulated financial adviser for tailored guidance.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Abeona Therapeutics' stock with a target price of $20.21, indicating strong growth potential.
Financial Health
Abeona Therapeutics is generating modest revenue and cash flow but faces challenges in growth.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring ABEO
Orphan Drug Moats: Leaders In Rare Disease
The FDA's rejection of PTC Therapeutics' drug for a rare genetic disorder has delayed a new treatment option and created a significant setback for the company. This regulatory decision strengthens the competitive position of companies with already-approved therapies for rare diseases, highlighting the value of a proven drug portfolio.
Published: August 20, 2025
Explore BasketGene Therapy's Regulatory Tailwind
Sarepta Therapeutics' stock surged after the FDA re-approved its gene therapy for muscular dystrophy, signaling a positive turn for the industry. This development creates a potential tailwind for other biotech companies specializing in novel treatments for rare genetic diseases.
Published: July 30, 2025
Explore BasketPioneers In Rare Disease Therapy
The FDA's approval of PTC Therapeutics' drug for the rare disorder PKU marks a significant advancement in metabolic disease treatment. This event creates an investment opportunity by highlighting the growth potential of other biopharmaceutical companies specializing in therapies for rare genetic conditions.
Published: July 29, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Clinical Milestones Ahead
Progress in trials or regulatory news can sharply re-rate the stock, though clinical setbacks are common and can quickly reverse gains.
Small-cap Volatility
With a market cap near $280M, Abeona can show large price swings; potential returns come with higher risk and financing sensitivity.
Rare Disease Focus
Targeting rare genetic disorders means high unmet medical need and potential partner interest, but patient populations are small and outcomes uncertain.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ARCELLX, INC.
Develops T-cell therapies for the treatment of cancer.
AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
